Replies to post #148200 on Biotech Values

[jq1234]

Genzyme is not testing Mozobil in oncology indication at all right now. Those trials are all investigator sponsored trials. The article you linked said all 46 patients with CR, which I know for sure is wrong. Check original article in Blood.

[genisi]

I find the fact that there are several compounds (peptide/nonpeptide antagonists, RNAi, or anti-CXCR4 mAb*) targeted to block the SDF-1/CXCR4 complex in clinical trials good for BLRX in the sense of validating the MOA.

http://www.ncbi.nlm.nih.gov/pubmed/22376154

* BMS-936564 isn't mentioned in the abs.